Semaglutide was associated with more than twice the risk for nonarteritic anterior ischemic optic neuropathy compared with SGLT2 inhibitors, although the absolute risk “remained low,” according to a ...
Monthly Prescribing Reference: Semaglutide Doubles Risk for Nonarteritic Anterior Ischemic Optic Neuropathy
Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay News — ...
Patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) appear to have a very low incidence of nonarteritic anterior ischemic optic neuropathy (NAION) when appropriately prescribed ...
Worsening of vision occurred within a few weeks after onset of symptoms in most eyes with nonarteritic anterior ischemic optic neuropathy (NAION) that progressed. Only a past episode in the other eye, ...
Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with type 2 ...
Renal & Urology News: Semaglutide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy
The use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is not associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) in patients with ...
Monthly Prescribing Reference: Semaglutide May Increase Risk for Nonarteritic Anterior Ischemic Optic Neuropathy
Anterior ischemic optic neuropathy (AION) occurs when there is not enough blood flow into the eye. This causes damage to the optic nerve, quickly leading to vision loss. There are two subtypes of AION ...
The Cardiology Advisor: Semaglutide Linked to Increased Risk for Ischemic Optic Neuropathy
Researchers evaluated potential associations between semaglutide exposure and ischemic optic neuropathy across various formulations and patient subgroups.